EXTRACORPOREAL PHOTOCHEMOTHERAPY IN THE TREATMENT OF TYPICAL AND ATYPICAL LICHEN PLANUS RUBRUM

Cover Page


Cite item

Full Text

Abstract

Background: Lichen planus rubrum (LPR) belongs to the group of papulosquamous dermatoses. Pathophysiology of this most common lichenic dermatosis is related to autoimmune destruction of basal keratinocytes. Treatment of LPR includes systemic corticosteroids, cytotoxic agents, immunosuppressants, aromatic retinoids, PUVA-therapy, as well as biological preparations (rituximab, efalizumab), which all are insufficiently effective and associated with multiple side effects and complications. Aim: To evaluate efficacy of extracorporeal photochemotherapy (EPCT) in generalized typical and atypical LPR. Materials and methods: We performed a prospective active-controlled cohort study. Thirty three patients with different types of LPR treated with EPCT were divided into 2 groups. Group 1 included 19 patients with typical generalized (including subacute and chronic) LPR, group 2, 14 patients with atypical (pigmented, follicular, hypertrophic, erosive ulcerated, vulvovaginal/ gingival syndrome) LPR. At 2 hours before a EPCT session patients were administered 8-methoxypsoralen, then mononuclear cells were isolated with a cell separator Haemonetics MCS+ and treated with UV A radiation (at a wavelength from 320 to 400  nm), then monocyte mass was reinfused to the patient. The treatment course consisted of 4  sessions performed every other day. Results: Positive clinical effect and satisfactory tolerability of EPCT were demonstrated in all 33 patients. In patients with generalized subacute typical LPR, EPCT promoted activation of natural immunosuppressive mechanisms (there was no correlation between CD8+ and HLA-DR+ , as well as between CD8+ and CD11b+: r=0.52 (р>0.05) and r=0.35 (р>0.05), respectively). In patients with generalized chronic LPR the treatment led to restoration of immune tolerance to genuine body antigens (correlation between CD16+ and CD11b+ was preserved and correlation between CD16+ and HLA-DR+ was lower: r=0.77 (p<0.05) and r=0.62 (p>0.05), respectively). Conclusion: The data obtained confirms high clinical efficacy of EPCT and its pathophysiological effects at early and later stages of generalized typical LPR.

About the authors

A. V. Molochkov

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: derma@monikiweb.ru
MD, PhD, Professor, Deputy Director on Science and International Communications Russian Federation

A. V. Kil'dyushevskiy

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Email: derma@monikiweb.ru
MD, PhD, Professor, Leading Research Fellow, Surgical Hemocorrection and Detoxication Department Russian Federation

Yu. V. Molochkova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Author for correspondence.
Email: derma@monikiweb.ru
MD, PhD, Senior Research Fellow, Dermatovenereology and Dermato-oncology Department Russian Federation

References

  1. Караулов АВ, Быков СА, Быков АС. Иммунология, микробиология и иммунопатология кожи. М.: БИНОМ-Пресс; 2012. 328 с.
  2. Молочков ВА, Молочков АВ, Переверзева ОЭ. К совершенствованию терапии красного плоского лишая. Российский журнал кожных и венерических болезней. 2011;(2):7–9.
  3. Wackernagel A, Legat FJ, Hofer A, Quehenberger F, Kerl H, Wolf P. Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus. Photodermatol Photoimmunol Photomed. 2007;23(1):15–9. doi: 10.1111/j.1600- 0781.2007.00261.x.
  4. McAleer MA, Murphy M, Bourke J. Retuximab therapy for resistant erosive lichen planus and pyoderma gangrenosum. Br J Dermatol. 2010;163(2):445.
  5. Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch Dermatol. 2006;142(6):680–2. doi: 10.1001/archderm.142.6.680.
  6. Zaraa I, Mahfoudh A, Sellami MK, Chelly I, El Euch D, Zitouna M, Mokni M, Makni S, Ben Osman A. Lichen planus pemphigoides: four new cases and a review of the literature. Int J Dermatol. 2013;52(4):406–12. doi: 10.1111/j.1365-4632.2012.05693.x.
  7. Schwarz T, Rutter A, Hawk J. Phototherapy and photochemotherapy: less common indications for its use. In: Krutmann J, Honigsmann H, Elmets CA, editors. Dermatological phototherapy and photodiagnostic methods. 2nd edition. Springer; 2009. p. 205–27.
  8. Молочков ВА, Кильдюшевский АВ, Молочков АВ, ред. Фотоферез в дерматовенерологии. М.: БИНОМ; 2014. 152 c.
  9. Kerdel FA, Romanelli P, Trent J. Dermatologic Therapeutics. A pocket guide. New York: McGraw-Hill; 2005. 420 p.
  10. Guyot AD, Farhi D, Ingen-Housz-Oro S, Bussel A, Parquet N, Rabian C, Bachelez H, Francès C. Treatment of refractory erosive oral lichen planus with extracorporeal photochemotherapy: 12 cases. Br J Dermatol. 2007;156(3):553–6. doi: 10.1111/j.1365- 2133.2006.07647.x.
  11. Marchesseau-Merlin AS, Perea R, Kanold J, Demeocq F, Souteyrand P, D'Incan M. Photopheresis: an alternative therapeutic approach in corticoresistant erosive oral lichen planus. Ann Dermatol Venereol. 2008;135(3):209–12. doi: 10.1016/j.annder.2007.06.010.
  12. Kunte C, Erlenkeuser-Uebelhoer I, Michelsen S, Scheerer-Dhungel K, Plewig G. Treatment of therapy-resistant erosive oral lichen planus with extracorporeal photopheresis (ECP). J Dtsch Dermatol Ges. 2005;3(11):889–94. doi: 10.1111/j.1610- 0387.2005.05759.x.
  13. Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, Ludvigsson J, Quaglino P, Reinisch W, Scarisbrick J, Schwarz T, Wolf P, Arenberger P, Assaf C, Bagot M, Barr M, Bohbot A, Bruckner-Tuderman L, Dreno B, Enk A, French L, Gniadecki R, Gollnick H, Hertl M, Jantschitsch C, Jung A, Just U, Klemke CD, Lippert U, Luger T, Papadavid E, Pehamberger H, Ranki A, Stadler R, Sterry W, Wolf IH, Worm M, Zic J, Zouboulis CC, Hillen U. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1:1–37. doi: 10.1111/jdv.12311.
  14. Adamski J, Kinard T, Ipe T, Cooling L. Extracorporeal photopheresis for the treatment of autoimmune diseases. Transfus Apher Sci. 2015;52(2):171–82. doi: 10.1016/j.transci.2015.02.005.
  15. Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Int J Dermatol. 2009;48(7):682–94. doi: 10.1111/j.1365-4632.2009.04062.x.
  16. Simon M Jr, Keller J. Subpopulations of T lymphocytes in peripheral blood and in skin lesions in lichen ruber planus. Dermatologica. 1984;169(3):112–6.
  17. Караулов АВ, Кильдюшевский АВ, Молочкова ЮВ. Клинико-иммунологические аспекты патогенеза красного плоского лишая. Иммунопатология, аллергология, инфектология. 2014;(2):91–8.
  18. Сергеев АЮ, Караулов АВ, Сергеев ЮВ. Иммунодерматология: иммунологические основы патогенеза главных воспалительных дерматозов человека. Иммунопатология, аллергология, инфектология. 2003;(3): 10–23.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Molochkov A.V., Kil'dyushevskiy A.V., Molochkova Y.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies